ClinicalTrials.gg
RecruitingNCT06464510NoVaUpdated Jan 30, 2026

Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis

A Phase 3 interventional study of Early Vasopressin and Norepinephrine and Vasopressin for Rescue in Septic Shock, sponsored by Hospital do Coracao. Recruiting at 8 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Hospital do Coracao · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic with a site in Brazil — 3 open to participants now, 4 under way, 4 of them phase 3. Shock, Septic · Brazil.

Planned enrollment
Largest of 25
2,800 · median 126
Started
2024
the only one that year
Phase 3
9 of 30
2 open now
Registered
28th of 30
by date

Among the 30 studies in Shock, Septic with a site in Brazil, this one has the largest planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 3, and was the 28th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

3 of the 30 studies in Shock, Septic with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic with a site in Brazil, or all of them as a file.
02

Study summary

The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.

Read the detailed description

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated body response to infection. Its most severe form, septic shock, occurs when underlying circulatory and cellular metabolic abnormalities are pronounced, indicating greater severity and higher mortality. Vasopressor use is a cornerstone aspect in the treatment of critically ill patients with sepsis-associated hemodynamic dysfunction, with norepinephrine, a catecholamine, being the vasopressor of choice.

Vasopressin is an endogenous peptide hormone with potential advantages over norepinephrine in a catecholamine-sparing strategy for treating sepsis-associated hemodynamic dysfunction.

This is a phase 3, multicenter, open-label, randomized controlled trial. Adult patients with sepsis-associated hemodynamic dysfunction in the ICU may be eligible to participate. We aim to enroll 2,800 patients.

03

Conditions studied

  • Septic Shock

Keywords

  • Vasopressin
  • Norepinephrine
  • Vasopressor dependent sepsis
  • Septic shock
  • Critically ill
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with vasopressor dependent sepsis, defined by infection suspicion and antibiotic administration or laboratory confirmed viral infection, plus hypotension with the need of vasopressors for at least one hour;
  • Admitted or expected to be admitted to the ICU in the next 12 hours
  • Adequate volume resuscitation in the opinion of the attending physician
  • Use of norepinephrine > 0.05μg/Kg/min and ≤ 0.25μg/Kg/min for at least 1 hour and at most 24 hours at the time of inclusion

Exclusion criteria

Exclusion Criteria:

  • Use of norepinephrine > 0.25μg/Kg/min in the last 24 hours, except when administered transiently in the context of sedation for a procedure or the initial phase of volume resuscitation for a period of less than one hour
  • Dialysis-dependent chronic kidney disease or acute kidney injury that received renal replacement therapy during current hospitalization or are expected to receive renal replacement therapy in the next 24 hours
  • Use of other vasopressors (except norepinephrine) at the moment of inclusion
  • Use of vasopressors for sepsis in the last 7 days
  • Suspected or confirmed acute mesenteric ischemia
  • Anaphylaxis or known to the study drug
  • Expect to die in the next 24 hours
  • Medical team not committed to full support at the time of inclusion
  • Previous inclusion in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,800 participants (estimated)

Study arms

  • Experimental
    Early Vasopressin

    After randomization, vasopressin will be initiated and titrated up to 0.04U/min to maintain the target mean arterial pressure (MAP). Concurrently, norepinephrine will be reduced, with the goal of using the maximum dose of vasopressin and minimizing or eliminating the use of norepinephrine, while still maintaining the target MAP.

    Drug: Early Vasopressin

  • Active comparator
    Norepinephrine plus vasopressin for rescue

    After randomization, norepinephrine will be titrated to maintain the target MAP. Vasopressin will be introduced as a rescue strategy only if the norepinephrine dose exceeds 0.5 μg/kg/min. Once vasopressin is initiated, it can be titrated up to 0.04U/min to help maintain the target MAP if the norepinephrine dose remains above 0.5 μg/kg/min.

    Drug: Norepinephrine and Vasopressin for Rescue

Interventions

  • DrugEarly Vasopressin

    Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.

  • DrugNorepinephrine and Vasopressin for Rescue

    Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.

06

What researchers measure

Primary outcomes

  1. All-cause mortality or renal replacement therapy

    Composite of all-cause mortality or renal replacement therapy within 28 days after randomization.

    Time frame: 28 days

Secondary outcomes

  1. All-cause mortality

    All-cause mortality within 28 days after randomization

    Time frame: 28 days

  2. Renal replacement-therapy

    Need of renal replacement therapy within 28 days after randomization.

    Time frame: 28 days

  3. Renal replacement-free days

    Renal-replacement free days are defined by the number of days a patient is alive and free of renal replacement support between randomization and day 28. Non-survivors will be considered to have zero renal replacement-free days.

    Time frame: 28 days

  4. ICU-free days

    Number of days a patient is alive and outside the ICU between randomization and day 28. Non-survivors will be considered to have zero ICU-free days.

    Time frame: 28 days

  5. Hospital-free days

    Number of days a patient is alive and outside the hospital between randomization and day 28. Non-survivors will be considered to have zero hospital-free days.

    Time frame: 28 days

  6. Organ support-free days and its components

    The definition of organ support involves three components: renal replacement therapy, invasive mechanical ventilation, and vasopressor use. Organ support-free days are defined by the number of days a patient is alive and free of all three organ support therapies between randomization and day 28. Non-survivors will be considered to have zero organ support-free days.

    Time frame: 28 days

  7. Cardiac arrhythmias

    Occurrence of cardiac arrhythmias between randomization and day 28

    Time frame: 28 days

  8. Ischemic events

    Occurrence of mesenteric ischemia, ischemic stroke, digital ischemia and acute coronary syndrome between randomization and day 28

    Time frame: 28 days

07

Study locations

4 of 8 sites recruiting
  • Hospital Geral de Caxias do Sul
    Caxias do Sul, Rio Grande do Sul, Brazil
    Recruiting
    • Emerson Silva · Contact
  • Hospital Nereu Ramos
    Florianópolis, Santa Catarina, Brazil
    Recruiting
  • Hospital SEPACO
    São Paulo, S, Brazil
    Not yet recruiting
    • Flávio Freitas · Contact
  • Hospital de Amor - Unidade Barretos (Fundação PIO XII)
    Barretos, São Paulo, Brazil
    Not yet recruiting
    • Cristina Amendola · Contact
  • Hospital do Coracao
    São Paulo, São Paulo 05435000, Brazil
    Recruiting
    • Marcelo Romano, MD · Contact
    • Luzia Taniguchi, MSc · Contact
  • BP-A Beneficiência Portuguesa de São Paulo
    São Paulo, São Paulo, Brazil
    Not yet recruiting
  • Hospital Alemão Oswaldo Cruz
    São Paulo, São Paulo, Brazil
    Not yet recruiting
    • Mino Cestari, MD · Contact
  • Hospital São Paulo - UNIFESP
    São Paulo, São Paulo, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Submission of a statistical analysis plan for the purposed analyses for the Steering Committee evaluation. Compliance with Brazilian data privacy law.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 1 year after study publication

Access criteria: Submission of a statistical analysis plan for the purposed analyses for the Steering Committee evaluation. Compliance with Brazilian data privacy law.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2027, 33 months after the start.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 33 months is below that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jun 18, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06464510
Lead sponsor
Hospital do Coracao
Collaborators
Brazilian Research In Intensive Care Network, National Institute of Science and Technology (INCT) in Precision Intensive Care Medicine
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Nov 21, 2024
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Bruno M Tomazini, MD
Contact
btomazini@hcor.com.br
+5511982839173
Alexandre Biasi Cavalcanti, PhD
Contact
abiasi@hcor.com.br
+551130536611
Bruno M Tomazini, MD
principal investigator · Hcor Research Institute
Machado R Flavia, PhD
study chair · Universidade Federal de São Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion